Alithea Genomics

Alithea Genomics is a platform company revolutionizing RNA sequencing by dramatically increasing throughput and reducing cost and labor. Its core technologies—MERCURIUS™ DRUG-seq for bulk screening, BRB-seq for bulk RNA, and FLASH-seq for single-cell analysis—eliminate the need for RNA extraction and allow hundreds of samples to be processed in a single tube. This positions the company as a key enabler for large-scale applications in drug discovery, biomarker development, and fundamental research. Alithea operates as a private, likely pre-revenue or early-revenue company, selling its optimized kits and solutions to research and pharmaceutical clients.

Suite of RNA sequencing technologies enabling extraction-free, massively multiplexed library preparation from diverse samples. Core technologies: MERCURIUS™ DRUG-seq (for high-throughput compound screening), BRB-seq (for bulk RNA-seq), and FLASH-seq (for single-cell RNA-seq).

Alithea competes in the high-throughput RNA-seq segment against large players like Illumina (library prep kits, NovaSeq), Thermo Fisher (Ion Torrent, TaqMan), and 10x Genomics (single-cell). It differentiates through its extreme multiplexing (384-plex) and extraction-free workflow, targeting a niche of ultra-high-sample-number studies where cost and labor are primary constraints. Niche players like Lexogen and SeqWell also offer multiplexing solutions.